Drug Trial News

RSS

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.

28 Oct 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

ETEC vaccine candidate provides significant protection against bacterial diarrhea

New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease.

28 Oct 2014

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.

28 Oct 2014

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.

27 Oct 2014

Bortezomib drug effective against chronic GVHD

Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease (GVHD), a common and debilitating side effect from allogeneic hematopoietic stem cell transplants.

27 Oct 2014

BRI receives FDA permission to conduct study of Antineoplastons A10 and AS2-1 in DIPG patients

Burzynski Research Institute, Inc. announced today that the U.S. Food and Drug Administration has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG).

25 Oct 2014

Human trial of second investigational Ebola vaccine candidate under way

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.

23 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease.

21 Oct 2014

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.

20 Oct 2014

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014.

20 Oct 2014

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.

20 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models.

16 Oct 2014

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th.

14 Oct 2014

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.

14 Oct 2014

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor, with various factors stacking the odds against successful treatment: early detection is uncommon, it tends to spread quickly and recurrence is likely. However, several newer approaches show promise in increasing the response rate to pancreatic cancer treatment.

10 Oct 2014

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMN Rx in infants and children with spinal muscular atrophy at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany.

10 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

Drug Trial News

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

ETEC vaccine candidate provides significant protection against bacterial diarrhea

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Bortezomib drug effective against chronic GVHD

BRI receives FDA permission to conduct study of Antineoplastons A10 and AS2-1 in DIPG patients

Human trial of second investigational Ebola vaccine candidate under way

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

High doses of fish oil supplements do not reduce atrial fibrillation

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

First study of promising Ebola vaccine commenced in West Africa

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News